Literature DB >> 4015724

Cellular immunity to collagen and laminin in scleroderma.

J E Huffstutter, F A DeLustro, E C LeRoy.   

Abstract

Peripheral blood mononuclear cells (PBMC) obtained from scleroderma patients and normal controls were cultured in the presence of types I and IV collagen, intima collagen, laminin, and phytohemagglutinin. PBMC from 9 of 19 patients (47%) demonstrated lymphocyte transformation in response to laminin, and those from 2 of 17 patients (12%) demonstrated reactivity to type IV collagen. None of the patient PBMC were responsive to type I collagen or to intima collagen. Healthy controls failed to demonstrate lymphocyte transformation in response to laminin or collagens. Analysis of clinical data, including age, disease duration, and degree of skin thickening and internal organ involvement, failed to predict the response to laminin or type IV collagen. The significance and disease specificity of this cellular immunity to laminin and, with lower frequency, to type IV collagen, that occurs in some scleroderma patients are unknown.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4015724     DOI: 10.1002/art.1780280708

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  11 in total

1.  A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease.

Authors:  Arnold E Postlethwaite; Weng Kee Wong; Philip Clements; Soumya Chatterjee; Barri J Fessler; Andrew H Kang; Joseph Korn; Maureen Mayes; Peter A Merkel; Jerry A Molitor; Larry Moreland; Naomi Rothfield; Robert W Simms; Edwin A Smith; Robert Spiera; Virginia Steen; Kenneth Warrington; Barbara White; Frederick Wigley; Daniel E Furst
Journal:  Arthritis Rheum       Date:  2008-06

2.  Antibodies to mouse laminin in patients with systemic sclerosis (scleroderma) recognize galactosyl (alpha 1-3)-galactose epitopes.

Authors:  A Gabrielli; M Candela; A M Ricciatti; M L Caniglia; J Wieslander
Journal:  Clin Exp Immunol       Date:  1991-12       Impact factor: 4.330

Review 3.  Pathogenesis of Systemic Sclerosis.

Authors:  Debendra Pattanaik; Monica Brown; Bradley C Postlethwaite; Arnold E Postlethwaite
Journal:  Front Immunol       Date:  2015-06-08       Impact factor: 7.561

4.  Prostacyclin in systemic lupus and anticardiolipin syndrome.

Authors:  R A Asherson; E N Harris; G R Hughes; J M Ritter; S E Barrow; M Jones
Journal:  Ann Rheum Dis       Date:  1987-05       Impact factor: 19.103

5.  Soluble interleukin-2 receptor, interleukin-2 and interleukin-4 in sera and supernatants from patients with progressive systemic sclerosis.

Authors:  G Famularo; A Procopio; R Giacomelli; C Danese; S Sacchetti; M A Perego; A Santoni; G Tonietti
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

Review 6.  A brief overview of the pathogenesis of scleroderma (systemic sclerosis).

Authors:  E C LeRoy
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

7.  Increased frequency of in vivo hprt gene-mutated T cells in the peripheral blood of patients with systemic sclerosis.

Authors:  P P Sfikakis; J Tesar; S Theocharis; G L Klipple; G C Tsokos
Journal:  Ann Rheum Dis       Date:  1994-02       Impact factor: 19.103

8.  Anti-collagen antibodies in systemic sclerosis and in primary Raynaud's phenomenon.

Authors:  L Riente; B Marchini; M P Dolcher; A Puccetti; S Bombardieri; P Migliorini
Journal:  Clin Exp Immunol       Date:  1995-11       Impact factor: 4.330

Review 9.  Pulmonary immunity and extracellular matrix interactions.

Authors:  David N O'Dwyer; Stephen J Gurczynski; Bethany B Moore
Journal:  Matrix Biol       Date:  2018-04-09       Impact factor: 11.583

10.  Characterisation of the immune response to type I collagen in scleroderma.

Authors:  Kenneth J Warrington; Usha Nair; Laura D Carbone; Andrew H Kang; Arnold E Postlethwaite
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.